3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Status
Recruiting
3
No longer available
1
Completed
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
2
Sarcoma
1
Plasma cell
1
Lymphoid
1
Conditions
Breast Neoplasms
11
Triple Negative Breast Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Multiple Myeloma
2
Meningeal Neoplasms
2
Lymphoma, Non-Hodgkin
2
HER2-positive Breast Cancer
2
Stomach Neoplasms
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Meningeal Carcinomatosis
1
Hemangiosarcoma
1
Colorectal Neoplasms
1
Brain Neoplasms
1
Adenocarcinoma
1
Interventions
Blood Specimen Collection
38
pembrolizumab
36
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
18
Exercise
17
Carboplatin
16
Nivolumab
15
atezolizumab
14
Cisplatin
14
Drug Therapy
13
Paclitaxel
12
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
12
Trastuzumab
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Pemetrexed
9
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
tucatinib
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT07193394
2026-02-23
H3RAKLES
Institut Curie
Phase 2
Recruiting
20 enrolled